WHO ICTRP trial
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)
JPRN-jRCT2080223740 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223740 |
|---|---|
| Public title | ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER) |
| Scientific title | A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis - AMBER |
| Primary sponsor | Novartis Pharma K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Japan;North America;Europe |
| Conditions | Autoimmune Hepatitis |
| Interventions | investigational material(s) Generic name etc : VAY736 Dosage and Administration : VAY736 Dose 1/Dose 2/Dose 3 control material(s) Generic name etc : Placebo Dosage and Administration: Placebo control |
| Registration date | Jun 12, 2017 |
| Target size | 5 |
| Secondary IDs | NCT03217422;JapicCTI-173796 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: